Navigation Links
UH Rainbow to study African-Americans' response to asthma medications
Date:5/2/2014

In a first-of-its-kind clinical trial, asthma researchers at University Hospitals Rainbow Babies & Children's Hospital (UH Rainbow) will evaluate treatment guidelines for African American children and young adults with asthma.

"Each year African Americans experience more asthma-related urgent care visits, hospitalizations and death rates compared to Caucasians," says James Chmiel, MD, Clinical Director of Pediatric Pulmonology at UH Rainbow and principal investigator of the UH Rainbow study site. Dr. Chmiel, who is also Associate Professor of Pediatrics at Case Western Reserve University School of Medicine, says one possible explanation is that African Americans respond differently to asthma therapies.

The study of Best African American Response to Asthma Drugs (BARD) will examine whether African Americans respond differently to asthma therapies compared to Caucasians and will help to identify the best add-on therapy based on the patients' age. Researchers are recruiting African American patients five years of age and older who have asthma. UH Rainbow is conducting this study as a member of nine partnerships known as AsthmaNet. AsthmaNet is a network of asthma researchers across the country conducting this and other asthma research studies, and is funded by the National Institutes of Health.

National asthma guidelines recommend increasing inhaled corticosteroids (ICS) or adding a long-acting beta agonist (LABA) to treat patients who have difficulty controlling symptoms on low doses of ICS. However, these guidelines are based on studies conducted in populations that were predominantly non-black. Evidence suggests African Americans may not respond to changes in asthma medications the same way other races do.

BARD will enroll several hundred patients nationally for 18 months. Study participants will receive low dose ICS, and if their asthma is inadequately controlled, they will receive four different treatments (low dose ICS plus LABA, medium dose ICS, medium dose ICS plus LABA, and high dose ICS) over four separate 14-week treatment periods.

"Results of the BARD study will allow for evidence-based recommendations for the use of asthma medications in African Americans, significantly impacting national asthma guidelines," says Dr. Chmiel.


'/>"/>

Contact: Katelyn McCarthy
katelyn.mccarthy@uhhospitals.org
216-767-8582
University Hospitals Case Medical Center
Source:Eurekalert

Related medicine news :

1. Rainbow research reveals young children with asthma visit emergency department most often
2. Voices Against Brain Cancer Applauds Mother For Starting Riah’s Rainbow Organization
3. Historic Lodge at Rainbow Trout Ranch Celebrates Eighty Five Years in Southern Colorado
4. Study shows link between sleep apnea and hospital maternal deaths
5. Vanderbilt study explores genetics behind Alzheimers resiliency
6. Study: Custom-made mouthguards reduce athletes risk of concussion
7. Study: Low-fat diet helps fatigue in people with MS
8. Space Station study seeks how plants sense up and down
9. Study confirms increased prevalence of GI symptoms among children with autism
10. Anti-smoking TV ads should use anger, Dartmouth-Cornell study suggests
11. $2.3M study to examine how neighborhoods influence child maltreatment rates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... 2017 , ... The Leaders Engaged on Alzheimer’s Disease ... in opposition to the President’s Fiscal Year 2018 Federal Budget Blueprint . ... for the most vulnerable among us. , The proposed budget would cut $15.1 ...
(Date:3/23/2017)... CA (PRWEB) , ... March 23, 2017 , ... ... customizable coding audit software solution, iCode Assurance, at HCCA’s 21st annual Compliance Institute ... and accelerates the coding audit process for all medical chart types with a ...
(Date:3/23/2017)... ... 2017 , ... Ogden Clinic, the largest multi-specialty group in ... to expand its focus on patient care by providing an advanced check-in and ... Ogden Clinic, we are working to become a different type of provider, one ...
(Date:3/22/2017)... ... ... Death anxiety is unconscious and needs understanding and non-judgmental support in a loving ... book titled “ As Good as Goodbyes Get ” (published by Balboa Press AU), ... experiencing at the bedside of patients who were dying. The book centers about questions ...
(Date:3/22/2017)... ... March 22, 2017 , ... The American Society for ... (PA) form for prescribers to improve patients’ access to the revolutionary therapy for ... as part of the article entitled “PCSK9 Inhibitor Access Barriers: Issues and ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... , 22. März 2017   VWR ... weltweit tätige Anbieter von Produkten und Dienstleistungen ... Erwerb von EPL Archives Inc. bekannt, eines ... Kunden im kompletten Zyklus regulierter Forschung, Entwicklung ... Proben, Speicherung von Dokumenten und Zusatzdienstleistungen zur ...
(Date:3/22/2017)... March 22, 2017 TapImmune, Inc. ... in the development of innovative peptide and gene-based ... disease, today announced that it will participate in ... Dr. Glynn Wilson , Chairman and CEO ... company,s business, clinical pipeline and partnering opportunities for ...
(Date:3/22/2017)... March 22, 2017 A new independent ... is the proven ultraviolet-C (UV-C) disinfection solution of ... (HAIs). Published in the March ... Control , the peer-reviewed study of UV-C disinfection ... Vancouver General Hospital and Rochester General Hospital. According ...
Breaking Medicine Technology: